January 08, 2005

Ocaperidone - New Schiz. Drug in Trials

It was reported this week that France-based Neuro3d, a biopharmaceutical company focused on psychiatric disorders, has raised $42.9 million in a third round of financing to advance the company's psychiatric drugs pipeline.

The company's drug portfolio includes ocaperidone in phase II trials for the treatment of schizophrenia, two new antidepressants with different mechanisms of actions in phase I trials and several drug candidates in research or pre-clinical development.

Source: Neuro3d, http://www.neuro3d.fr

For more information:


Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required